Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.

Lexaria Bioscience is revolutionizing drug delivery with its DehydraTECH™ technology, enhancing oral absorption of medications and enabling drugs to cross the blood-brain barrier more effectively.

Lexaria Bioscience is revolutionizing the landscape of weight loss treatments with its cutting-edge oral delivery technology.